These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1142 related items for PubMed ID: 8520092

  • 1. Desogestrel, norgestimate, and gestodene: the newer progestins.
    Kaplan B.
    Ann Pharmacother; 1995; 29(7-8):736-42. PubMed ID: 8520092
    [Abstract] [Full Text] [Related]

  • 2. Clinical aspects of three new progestogens: desogestrel, gestodene, and norgestimate.
    Chez RA.
    Am J Obstet Gynecol; 1989 May; 160(5 Pt 2):1296-300. PubMed ID: 2524163
    [Abstract] [Full Text] [Related]

  • 3. Characteristics of the new progestogens in combination oral contraceptives.
    Rebar RW, Zeserson K.
    Contraception; 1991 Jul; 44(1):1-10. PubMed ID: 1832625
    [Abstract] [Full Text] [Related]

  • 4. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel.
    Teichmann A.
    Int J Fertil Menopausal Stud; 1995 Jul; 40 Suppl 2():98-104. PubMed ID: 8574257
    [Abstract] [Full Text] [Related]

  • 5. The new era in oral contraception: pills containing gestodene, norgestimate, and desogestrel.
    London RS.
    Obstet Gynecol Surv; 1992 Nov; 47(11):777-82. PubMed ID: 1436906
    [Abstract] [Full Text] [Related]

  • 6. Norgestimate: a clinical overview of a new progestin.
    Bringer J.
    Am J Obstet Gynecol; 1992 Jun; 166(6 Pt 2):1969-77. PubMed ID: 1605287
    [Abstract] [Full Text] [Related]

  • 7. A norgestimate-containing oral contraceptive: review of clinical studies.
    Kafrissen ME.
    Am J Obstet Gynecol; 1992 Oct; 167(4 Pt 2):1196-202. PubMed ID: 1415446
    [Abstract] [Full Text] [Related]

  • 8. A comparative metabolic study of two low-estrogen-dose oral contraceptives containing desogestrel or gestodene progestins.
    Crook D, Godsland IF, Worthington M, Felton CV, Proudler AJ, Stevenson JC.
    Am J Obstet Gynecol; 1993 Nov; 169(5):1183-9. PubMed ID: 8238183
    [Abstract] [Full Text] [Related]

  • 9. Influence of gestodene and desogestrel as components of low-dose oral contraceptives on the pharmacokinetics of ethinyl estradiol (EE2), on serum CBG and on urinary cortisol and 6 beta-hydroxycortisol.
    Hammerstein J, Daume E, Simon A, Winkler UH, Schindler AE, Back DJ, Ward S, Neiss A.
    Contraception; 1993 Mar; 47(3):263-81. PubMed ID: 8462317
    [Abstract] [Full Text] [Related]

  • 10. Estrogen and progestin components of oral contraceptives: relationship to vascular disease.
    Carr BR, Ory H.
    Contraception; 1997 May; 55(5):267-72. PubMed ID: 9220222
    [Abstract] [Full Text] [Related]

  • 11. New progestogens in oral contraception.
    Fotherby K, Caldwell AD.
    Contraception; 1994 Jan; 49(1):1-32. PubMed ID: 8137623
    [Abstract] [Full Text] [Related]

  • 12. Effect of oral contraceptive progestins on serum copper concentration.
    Berg G, Kohlmeier L, Brenner H.
    Eur J Clin Nutr; 1998 Oct; 52(10):711-5. PubMed ID: 9805216
    [Abstract] [Full Text] [Related]

  • 13. Gestodene. A review of its pharmacology, efficacy and tolerability in combined contraceptive preparations.
    Wilde MI, Balfour JA.
    Drugs; 1995 Aug; 50(2):364-95. PubMed ID: 8521763
    [Abstract] [Full Text] [Related]

  • 14. Comparative pharmacology of newer progestogens.
    Kuhl H.
    Drugs; 1996 Feb; 51(2):188-215. PubMed ID: 8808163
    [Abstract] [Full Text] [Related]

  • 15. Preclinical evaluation of norgestimate, a progestin with minimal androgenic activity.
    Phillips A, Hahn DW, McGuire JL.
    Am J Obstet Gynecol; 1992 Oct; 167(4 Pt 2):1191-6. PubMed ID: 1415445
    [Abstract] [Full Text] [Related]

  • 16. A cross-over study of three oral contraceptives containing ethinyloestradiol and either desogestrel or levonorgestrel.
    Song S, Chen JK, Yang PJ, He ML, Li LM, Fan BC, Rekers H, Fotherby K.
    Contraception; 1992 Jun; 45(6):523-32. PubMed ID: 1535580
    [Abstract] [Full Text] [Related]

  • 17. Effect of two oral contraceptives containing ethinyl estradiol and gestodene or norgestimate on different lipid and lipoprotein parameters.
    Wiegratz I, Jung-Hoffmann C, Gross W, Kuhl H.
    Contraception; 1998 Aug; 58(2):83-91. PubMed ID: 9773262
    [Abstract] [Full Text] [Related]

  • 18. The new pills: awaiting the next generation of oral contraceptives.
    Klitsch M.
    Fam Plann Perspect; 1992 Aug; 24(5):226-8. PubMed ID: 1426186
    [Abstract] [Full Text] [Related]

  • 19. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism.
    Godsland IF, Crook D, Simpson R, Proudler T, Felton C, Lees B, Anyaoku V, Devenport M, Wynn V.
    N Engl J Med; 1990 Nov 15; 323(20):1375-81. PubMed ID: 2146499
    [Abstract] [Full Text] [Related]

  • 20. Venous thromboembolism and desogestrel- or gestodene-containing combination oral contraceptives: what are the facts?
    Contracept Rep; 1996 Apr 15; 7(1):3-6. PubMed ID: 12320047
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 58.